Page 147 - FINAL PROGRAM

Endometriosis, endometrium, implantation and fallopian tube
P-272 Syndecan-4 expression is upregulated in endometriosis and contributes to an invasive phenotype
M. Götte (Germany)
P-273 The use of resveratrol for pain in endometriosis – a randomized clinical trial
R. Savaris (Brazil)
P-274 The prevalence of high risk human papillomavirus in ovarian endometriosis
M. Derakhshan-Horeh (Iran)
P-275 MK2206 and U0126 synergistically inhibit proliferation of deep endometriotic stromal cells and autophagy inhibition enhances the therapeutic effects of the combination therapy in vitro
S. Matsuzaki (France)
P-276 A meta-analysis of impact of endometrial cavity uid on assisted reproductive technology outcomes
S. Liu (China)
P-277 MiR-125b regulates endometrial receptivity by targeting MMP26 in women undergoing IVF-ET with elevated progesterone on HCG priming day
C. Chen (China)
P-278 A new innovative method, the uterine immune pro ling increases the live birth rate: a non-randomized control study
N. Lédée (France)
P-279 Single-cell transcriptome analysis of endometrial tissue
K. Krjutskov (Sweden)
P-280 Endometrial stromal cell-derived CX3CL1 promotes CX3CR1 expression and differentiation of CD4+Foxp3+ regulatory T cell in the endometriotic milieu
W. Yun (China)
P-281 Risk of miscarriage in women with endometriosis: insights from IVF cycles
M. Reschini (Italy)
P-282 Pregnancy outcome in women with endometriosis achieving pregnancy with in vitro fertilization
L. Benaglia (Italy)
P-283 Can the intrauterine infusion of hCG improve ART outcomes? Unsafe and con icting results in meta-analyses
F. Dieamant (Brazil)
FINAL PROGRAMME I HELSINKI, FINLAND – 3 TO 6 JULY 2016 143
POSTERS